Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 14, 2018 | June 15, 2018 |
| Annexon, Inc.ANNX · Entity 5011 | Director | June 11, 2026 | June 15, 2026 |
| AxonPrime Infrastructure Acquisition Corp[APMI] · Entity 136141 | Director | August 12, 2021 | August 13, 2021 |
| IMMUNIC, INC.VTL · Entity 6306 | Director · 10% owner | September 13, 2018 | September 18, 2018 |
| Rein Therapeutics, Inc.ALRN · Entity 7071 | Director · See Remarks | January 08, 2021 | January 08, 2021 |
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | Director · 10% owner | June 18, 2019 | June 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 14, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2028-06-14 | Direct | 12,500 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 12,500 · Balance 12,500 F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company.
Annexon, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-11 | Direct | 65,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 65,000 · Balance 65,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.
AxonPrime Infrastructure Acquisition Corp
Report date August 12, 2021 · Filed August 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-08-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-257777) under the heading "Description of Securities-Founder Shares," the shares of Class B Common Stock will automatically convert into shares of Class A Common Stock at the time of the initial business combination of the Issuer on a one-for-one basis, subject to certain adjustments, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-257777) under the heading "Description of Securities-Founder Shares," the shares of Class B Common Stock will automatically convert into shares of Class A Common Stock at the time of the initial business combination of the Issuer on a one-for-one basis, subject to certain adjustments, and have no expiration date.
IMMUNIC, INC.
Report date September 13, 2018 · Filed September 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 7,492,277 |
Reported balance
After 2018-09-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-09-13 · Sale · Disposed 3,890,000 · Balance 7,492,277 F1: The amount in Column 4 includes (a) 1,436,391 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,001,131 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 1,452,478 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.41 to $0.598. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (2) to this Form 4. F3: The amount in Column 5 includes (a) 2,766,539 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,928,216 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,797,522 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 7,044,777 |
Reported balance
After 2018-09-14 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-09-14 · Sale · Disposed 447,500 · Balance 7,044,777 F4: The amount in Column 4 includes (a) 165,240 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 115,169 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c)167,091 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (4), except to the extent of his pecuniary interest. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.40. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (5) to this Form 4. F6: The amount in Column 5 includes (a) 2,601,299 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (6), except to the extent of his pecuniary interest. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2018-09-17 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2018-09-17 · Sale · Disposed 7,044,777 · Balance 0 F7: The amount in Column 4 includes (a) 2,601,299 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (7), except to the extent of his pecuniary interest. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.3646. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (8) to this Form 4. F9: All shares previously held by (a) the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee, (b) by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager, and (c) Satter Medical Technology Partners, L.P. for which the Reporting Person had sole voting and dispositive power over all such shares, have been disposed of as of the date of the filing of this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The amount in Column 4 includes (a) 1,436,391 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,001,131 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 1,452,478 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.41 to $0.598. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (2) to this Form 4.
F3: The amount in Column 5 includes (a) 2,766,539 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,928,216 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,797,522 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.
F4: The amount in Column 4 includes (a) 165,240 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 115,169 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c)167,091 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (4), except to the extent of his pecuniary interest.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.40. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (5) to this Form 4.
F6: The amount in Column 5 includes (a) 2,601,299 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (6), except to the extent of his pecuniary interest.
F7: The amount in Column 4 includes (a) 2,601,299 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (7), except to the extent of his pecuniary interest.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.3646. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (8) to this Form 4.
F9: All shares previously held by (a) the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee, (b) by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager, and (c) Satter Medical Technology Partners, L.P. for which the Reporting Person had sole voting and dispositive power over all such shares, have been disposed of as of the date of the filing of this Form 4.
Rein Therapeutics, Inc.
Report date January 08, 2021 · Filed January 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 16,609,449 |
Reported balance
After 2021-01-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-01-08 · Purchase · Acquired 9,000,000 · Balance 16,609,449 F1: Reflects shares that were purchased from the Issuer on January 8, 2021 in a registered direct offering pursuant to a Securities Purchase Agreement, dated January 6, 2021. The amount in Column 4 includes (a) 863,636 shares purchased by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 863,636 shares purchased by various trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares and (c) 7,272,728 shares purchased by Satter Medical Technology Partners, L.P. ("SMTP") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest therein. F2: The amount in Column 5 includes (a) 1,025,076 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,231,044 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares that were purchased from the Issuer on January 8, 2021 in a registered direct offering pursuant to a Securities Purchase Agreement, dated January 6, 2021. The amount in Column 4 includes (a) 863,636 shares purchased by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 863,636 shares purchased by various trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares and (c) 7,272,728 shares purchased by Satter Medical Technology Partners, L.P. ("SMTP") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest therein.
F2: The amount in Column 5 includes (a) 1,025,076 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,231,044 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest therein.
Whitehawk Therapeutics, Inc.
Report date June 18, 2019 · Filed June 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2029-06-18 | Direct | 21,400 |
Reported balance
After 2019-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-18 · Grant · Acquired 21,400 · Balance 21,400 F1: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 29, 2018 Filed Dec 1, 2018 02:00 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.01 | $40,118.00 |
DisclosureSEC source: 0000899243-18-029916 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,118,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.89 to $2.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| November 28, 2018 Filed Dec 1, 2018 02:00 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.94 | $38,714.00 |
DisclosureSEC source: 0000899243-18-029916 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,098,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.78 to $2.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 01:30 UTC | IMMUNIC, INC. VTL · Entity 6306 | SaleCommon Stock | 7,044,777 | $0.29 | $2,054,256.97 |
DisclosureSEC source: 0001280776-18-000089 · wf-form4_153723423594630.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F7 · shares: The amount in Column 4 includes (a) 2,601,299 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (7), except to the extent of his pecuniary interest. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.3646. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (8) to this Form 4. F9 · ownership.nature: All shares previously held by (a) the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee, (b) by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager, and (c) Satter Medical Technology Partners, L.P. for which the Reporting Person had sole voting and dispositive power over all such shares, have been disposed of as of the date of the filing of this Form 4. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 01:30 UTC | IMMUNIC, INC. VTL · Entity 6306 | SaleCommon Stock | 447,500 | $0.36 | $160,384.00 |
DisclosureSEC source: 0001280776-18-000089 · wf-form4_153723423594630.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,044,777 F4 · shares: The amount in Column 4 includes (a) 165,240 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 115,169 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c)167,091 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (4), except to the extent of his pecuniary interest. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.40. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (5) to this Form 4. F6 · ownership.nature: The amount in Column 5 includes (a) 2,601,299 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (6), except to the extent of his pecuniary interest. Read SEC document |
| September 13, 2018 Filed Sep 18, 2018 01:30 UTC | IMMUNIC, INC. VTL · Entity 6306 | SaleCommon Stock | 3,890,000 | $0.50 | $1,930,996.00 |
DisclosureSEC source: 0001280776-18-000089 · wf-form4_153723423594630.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 7,492,277 F1 · shares: The amount in Column 4 includes (a) 1,436,391 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,001,131 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 1,452,478 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.41 to $0.598. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 2,766,539 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,928,216 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,797,522 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 20:17 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 1,818,182 | $3.85 | $7,000,000.70 |
DisclosureSEC source: 0000899243-18-018724 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,078,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 22:14 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017757 · doc4.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2028-06-20 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 12:17 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 12,500 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001562180-18-003019 · primarydocument.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-06-14 F1 · shares: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. Read SEC document |
| May 23, 2018 Filed May 25, 2018 20:07 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 29,538 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001280776-18-000038 · wf-form4_152727880596273.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,538 Underlying: Common Stock · 29,538 shares Expires 2028-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders. Read SEC document |
| March 23, 2018 Filed Mar 23, 2018 22:23 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 1,000 | $5.00 | $5,000.00 |
DisclosureSEC source: 0000899243-18-008446 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,259,835 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 22:23 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 4,000 | $4.85 | $19,390.00 |
DisclosureSEC source: 0000899243-18-008446 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,258,835 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.70 to 5.00. The reporting person undertakes to provide Aerpio Pharmaceuticals, Inc., any security holder of Aerpio Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| March 20, 2018 Filed Mar 21, 2018 20:52 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 5,400 | $4.97 | $26,860.14 |
DisclosureSEC source: 0000899243-18-008259 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,254,835 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.00. The reporting person undertakes to provide Aerpio Pharmaceuticals, Inc., any security holder of Aerpio Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 20:52 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 7,600 | $4.96 | $37,724.88 |
DisclosureSEC source: 0000899243-18-008259 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,249,435 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.95 to $5.00. The reporting person undertakes to provide Aerpio Pharmaceuticals, Inc., any security holder of Aerpio Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 13, 2017 Filed Dec 14, 2017 23:47 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 50,000 | $5.57 | $278,570.00 |
DisclosureSEC source: 0001280776-17-000104 · wf-form4_151329524009150.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 11,382,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.225 to $5.70. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 23:47 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 50,000 | $5.40 | $269,765.00 |
DisclosureSEC source: 0001280776-17-000104 · wf-form4_151329524009150.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 11,332,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.00 to $5.85. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 11, 2017 Filed Dec 11, 2017 22:35 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 50,000 | $4.96 | $248,225.00 |
DisclosureSEC source: 0001280776-17-000102 · wf-form4_151303170349004.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 11,282,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.80 to $5.05. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (5) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 08, 2017 Filed Dec 11, 2017 22:35 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 50,000 | $4.92 | $246,185.00 |
DisclosureSEC source: 0001280776-17-000102 · wf-form4_151303170349004.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 11,232,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.775 to $5.05. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 22:35 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 50,000 | $4.77 | $238,730.00 |
DisclosureSEC source: 0001280776-17-000102 · wf-form4_151303170349004.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 11,182,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.475 to $5.00. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| September 14, 2017 Filed Sep 14, 2017 23:40 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 30,000 | $4.25 | $127,539.00 |
DisclosureSEC source: 0001280776-17-000091 · wf-form4_150543243848119.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 11,132,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.075 to $4.45. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (5) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:40 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 50,000 | $4.13 | $206,465.00 |
DisclosureSEC source: 0001280776-17-000091 · wf-form4_150543243848119.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 11,102,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.90 to $4.20. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 23:40 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 50,000 | $3.74 | $187,225.00 |
DisclosureSEC source: 0001280776-17-000091 · wf-form4_150543243848119.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 11,052,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.625 to $3.90. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 20:14 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 50,000 | $3.53 | $176,615.00 |
DisclosureSEC source: 0001280776-17-000086 · wf-form4_150524726233137.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 11,002,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.25 to $3.65. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:14 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries F Preferred Stock · Derivative | 247,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018008 · doc4.xml · derivative · entry 6 Satter Muneer A · CIK 0001315797 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 24,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are held by the Muneer A. Satter Revocable Trust and various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:14 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries E-3 Preferred Stock · Derivative | 159,548 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018008 · doc4.xml · derivative · entry 5 Satter Muneer A · CIK 0001315797 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 16,055 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are held by the Muneer A. Satter Revocable Trust and various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:14 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries E-2 Preferred Stock · Derivative | 183,944 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018008 · doc4.xml · derivative · entry 4 Satter Muneer A · CIK 0001315797 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 18,511 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are held by the Muneer A. Satter Revocable Trust and various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:14 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries D Preferred Stock · Derivative | 847,721 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018008 · doc4.xml · derivative · entry 3 Satter Muneer A · CIK 0001315797 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 85,309 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are held by the Muneer A. Satter Revocable Trust and various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:14 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 33,333 | $15.00 | $499,995.00 |
DisclosureSEC source: 0000899243-17-018008 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 178,106 F2 · ownership.nature: These shares are held by the Muneer A. Satter Revocable Trust and various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:14 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionCommon Stock | 144,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-018008 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 144,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: These shares are held by the Muneer A. Satter Revocable Trust and various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares. Read SEC document |
| July 05, 2017 Filed Jul 11, 2017 20:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | PurchaseCommon Stock | 1,034,482 | $14.50 | $14,999,989.00 |
DisclosureSEC source: 0000899243-17-018170 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,037,042 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. in connection with the Issuer's registered public offering of common stock. F2 · ownership.nature: The amount in Column 5 includes (a) 785,340 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,217,220 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:05 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 12,500 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001562180-17-002295 · primarydocument.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-15 F1 · derivative.exercise_date: 100% of the option shares vest on the first anniversary of the date of grant (the "Vesting Date"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board of Directors through the Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for vesting acceleration upon a "Change in Control" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement. Read SEC document |
| June 14, 2017 Filed Jun 14, 2017 21:13 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 10,000 | $3.10 | $31,008.00 |
DisclosureSEC source: 0001280776-17-000072 · wf-form4_149747478861937.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,952,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.025 to $3.25. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 21:13 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 10,000 | $3.03 | $30,311.00 |
DisclosureSEC source: 0001280776-17-000072 · wf-form4_149747478861937.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,942,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.95 to $3.10. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| June 12, 2017 Filed Jun 12, 2017 20:05 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 10,000 | $3.06 | $30,615.00 |
DisclosureSEC source: 0001280776-17-000061 · wf-form4_149729794029409.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,932,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.975 to $3.20. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (5) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:05 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 10,000 | $3.17 | $31,733.00 |
DisclosureSEC source: 0001280776-17-000061 · wf-form4_149729794029409.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,922,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.95 to $3.25. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:05 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 10,000 | $3.10 | $30,958.00 |
DisclosureSEC source: 0001280776-17-000061 · wf-form4_149729794029409.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,912,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.975 to $3.275. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| June 07, 2017 Filed Jun 7, 2017 23:15 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 10,000 | $3.21 | $32,074.00 |
DisclosureSEC source: 0001280776-17-000057 · wf-form4_149687731692993.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,902,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.125 to $3.25. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (4) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| June 06, 2017 Filed Jun 7, 2017 23:15 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 10,000 | $3.19 | $31,940.00 |
DisclosureSEC source: 0001280776-17-000057 · wf-form4_149687731692993.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,892,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.675 to $3.45. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| May 23, 2017 Filed May 25, 2017 21:41 UTC | IMMUNIC, INC. VTL · Entity 6306 | GrantStock Option (right to buy) · Derivative | 63,031 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001280776-17-000053 · wf-form4_149574844517420.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,031 Underlying: Common Stock · 63,031 shares Expires 2027-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from May 23, 2017 or the day prior to the Company's 2018 annual meeting of stockholders. Read SEC document |
| March 27, 2017 Filed Mar 27, 2017 22:02 UTC | IMMUNIC, INC. VTL · Entity 6306 | PurchaseCommon Stock | 3,750,000 | $4.00 | $15,000,000.00 |
DisclosureSEC source: 0001280776-17-000017 · wf-form4_149065216093806.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 10,882,277 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. in connection with the Issuer's registered public offering of common stock. F2 · ownership.nature: The amount in Column 5 includes (a) 4,202,930 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 2,929,347 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 3,750,000 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 23:34 UTC | Whitehawk Therapeutics, Inc. NONE · Entity 6074 | PurchaseCommon Stock | 1,120,000 | $5.00 | $5,600,000.00 |
DisclosureSEC source: 0000899243-17-008099 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,241,835 F1 · kind: Represents shares acquired by Satter Medical Technology Partners, L.P. in a private placement offering by the Company that occurred immediately following the merger of a wholly-owned subsidiary of the Company with and into Aerpio Therapeutics, Inc. F1 · shares: Represents shares acquired by Satter Medical Technology Partners, L.P. in a private placement offering by the Company that occurred immediately following the merger of a wholly-owned subsidiary of the Company with and into Aerpio Therapeutics, Inc. F2 · balance_after: The amount in Column 5 includes (a) 980,124 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,141,711 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 1,120,000 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest. F2 · ownership.nature: The amount in Column 5 includes (a) 980,124 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,141,711 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 1,120,000 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.